세계의 신경유전학적 검사 시장 보고서(2025년)

Neurogenetic testing is a form of genetic testing that focuses on identifying genetic variations linked to neurological disorders or conditions impacting the nervous system. It aids in diagnosis, prediction, and management of neurological disorders, supports research, and helps develop personalized treatment strategies in neurology and genetics.

The main types of neurogenetic testing in the market include microarray analysis, whole-exome sequencing (WES), multiplex ligation-dependent probe amplification (MLPA), polymerase chain reaction (PCR) tests, and others. Microarray analysis is a technique in neurogenetic testing that simultaneously assesses the expression levels of thousands of genes. These tests are used for various diseases such as rare genetic disorders, cancer, cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy, thalassemia, Huntington's disease, fragile X syndrome, and others. They are utilized by hospitals, specialty clinics, research institutes, and diagnostics laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The neurogenetic testing market research report is one of a series of new reports from The Business Research Company that provides neurogenetic testing market statistics, including neurogenetic testing industry global market size, regional shares, competitors with a neurogenetic testing market share, detailed neurogenetic testing market segments, market trends, and opportunities, and any further data you may need to thrive in the neurogenetic testing industry. This neurogenetic testing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurogenetic testing market size has grown rapidly in recent years. It will grow from $0.61 billion in 2024 to $0.7 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to increased prevalence of neurological disease cases, increase research in life science domain, increasing prevalence of parkinson's disease, increased cases of cancer, and rising awareness among healthcare professionals.

The neurogenetic testing market size is expected to see rapid growth in the next few years. It will grow to $1.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to expanding applications in personalized medicine, rise in chronic diseases, increased number of hospitals, increased number of diagnostic laboratories and growing demand for early disease detection. Major trends in the forecast period include technological advancement, greater adoption of non-invasive testing methods, new product development, strategic collaborations, and the emergence of novel biomarkers for neurological conditions.

The forecast of 12.7% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. precision neurology by increasing costs for whole-exome sequencing kits and Artificial intelligence-based variant interpretation software imported from South Korea and Finland, potentially delaying diagnoses and raising neurogenetics laboratory operational costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increase in neurological disorders is expected to drive the growth of the neurogenetic testing market. Neurological disorders encompass conditions affecting the nervous system, including the brain, spinal cord, and nerves. These disorders can arise from genetic predisposition, infections, trauma, toxins, autoimmune responses, or degeneration. Neurogenetic testing plays a crucial role in enhancing the diagnosis, treatment, and management of neurological disorders. It provides personalized insights into genetic risk factors, guides treatment decisions, and empowers patients and families to make informed healthcare choices, thereby improving patient care and outcomes. For example, as reported by the European Brain Council in April 2022, millions globally suffer from over 600 neurological diseases and nearly 300 psychiatric conditions, including 65 million with epilepsy. In Europe, 10.5 million people have dementia, with projections indicating a rise to 18.7 million by 2050. Hence, the increasing prevalence of neurological disorders is expected to fuel the growth of the neurogenetic testing market.

The rising prevalence of cancer is also expected to boost the neurogenetic testing market. Cancer, characterized by uncontrolled cell division and tissue destruction, is on the rise due to factors such as the obesity epidemic, inherited genetic abnormalities, and viral infections such as hepatitis B and C, Epstein-Barr virus (EBV), and human papillomavirus (HPV). Neurogenetic testing is crucial for cancer management as it aids in selecting the most effective treatment, assessing prognoses, identifying high-risk patients, and providing personalized care based on individual genetic profiles and family history. For instance, the American Society of Clinical Oncology reported in May 2024 that an estimated 20 million new cancer cases were identified in 2022, with projections of 35 million new cases globally by 2050, leading to 9.7 million deaths from the disease. Consequently, the increasing prevalence of cancer is propelling the growth of the neurogenetic testing market.

Major companies are focusing on developing innovative products such as whole-genome sequencing to improve genetic analysis accuracy and scope. Whole-genome sequencing (WGS) is a comprehensive genetic testing method that involves determining an individual's entire genome DNA sequence. For instance, Nucleus Genomics, a US-based company specializing in genetic analysis, launched a DNA analysis product in March 2024. This platform provides people with a deeper understanding of their genetic predispositions, enabling informed decisions about health and well-being. Nucleus Genomics aims to redefine genetic testing by offering cutting-edge technology and expert genetic counseling services, making whole-genome sequencing accessible and revolutionizing genomic medicine.

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children's, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

North America was the largest region in the neurogenetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurogenetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurogenetic testing market includes revenues earned by entities by providing services such as diagnostic testing, predictive testing, carrier screening, and prenatal testing and related products such as genetic testing kits, DNA sequencing platforms, and bioinformatics software. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurogenetic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurogenetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurogenetic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurogenetic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Microarray Analysis; Whole-Exome Sequencing (WES); Multiplex Ligation Dependent Probe Amplification (MLPA); Polymerase Chain Reaction (PCR) Tests; Other Types
• 2) By Disease: Rare Genetic Disorder; Cancer; Cystic Fibrosis; Sickle Cell Anemia; Duchenne Muscular Dystrophy; Thalassemia; Huntington's Disease; Fragile X Syndrome; Other Diseases
• 3) By End-Users: Hospitals; Specialty Clinics; Research Institutes; Diagnostics Laboratories
• Subsegments:
• 1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray; Single Nucleotide Polymorphism (SNP) Microarray; Gene Expression Microarray
• 2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing; Clinical Exome Sequencing; Research-Grade Exome Sequencing
• 3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation; MLPA For Methylation Analysis; MLPA For Specific Disease Detection
• 4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR); Reverse Transcription PCR (RT-PCR); Digital PCR (dPCR)
• 5) By Other Types: Next-Generation Sequencing (NGS); Southern Blotting; Fluorescence In Situ Hybridization (FISH); Sanger Sequencing
• Companies Mentioned: Thermo Fisher Scientific Inc.; Mayo Clinic; Roche Diagnostics Corporation; Laboratory Corporation; Quest Diagnostics Incorporated; Eurofins Scientific Inc.; Agilent Technologies Inc.; PerkinElmer Inc.; Illumina Inc.; Bio-Rad Laboratories Inc.; QIAGEN N.V.; Exact Sciences Corporation; Myriad Genetics Inc.; BioReference Laboratories Inc.; Connecticut Children's; Invitae Corp.; Ambry Genetics Corporation; Fulgent Genetics Inc.; Blueprint Genetics Inc.; GeneDx LLC; Pacific Biosciences of California Inc.; MedGenome Labs; CENTOGENE; Baylor Genetics; Victorian Clinical Genetics Services
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurogenetic Testing Market Characteristics

3. Neurogenetic Testing Market Trends And Strategies

4. Neurogenetic Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Neurogenetic Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurogenetic Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurogenetic Testing Market Growth Rate Analysis
• 5.4. Global Neurogenetic Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurogenetic Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurogenetic Testing Total Addressable Market (TAM)

6. Neurogenetic Testing Market Segmentation

• 6.1. Global Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Microarray Analysis
• Whole-Exome Sequencing (WES)
• Multiplex Ligation Dependent Probe Amplification (MLPA)
• Polymerase Chain Reaction (PCR) Tests
• Other Types
• 6.2. Global Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rare Genetic Disorder
• Cancer
• Cystic Fibrosis
• Sickle Cell Anemia
• Duchenne Muscular Dystrophy
• Thalassemia
• Huntington's Disease
• Fragile X Syndrome
• Other Diseases
• 6.3. Global Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostics Laboratories
• 6.4. Global Neurogenetic Testing Market, Sub-Segmentation Of Microarray Analysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Comparative Genomic Hybridization (CGH) Microarray
• Single Nucleotide Polymorphism (SNP) Microarray
• Gene Expression Microarray
• 6.5. Global Neurogenetic Testing Market, Sub-Segmentation Of Whole-Exome Sequencing (WES), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Exome Sequencing
• Clinical Exome Sequencing
• Research-Grade Exome Sequencing
• 6.6. Global Neurogenetic Testing Market, Sub-Segmentation Of Multiplex Ligation Dependent Probe Amplification (MLPA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• MLPA For Copy Number Variation
• MLPA For Methylation Analysis
• MLPA For Specific Disease Detection
• 6.7. Global Neurogenetic Testing Market, Sub-Segmentation Of Polymerase Chain Reaction (PCR) Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Quantitative PCR (qPCR)
• Reverse Transcription PCR (RT-PCR)
• Digital PCR (dPCR)
• 6.8. Global Neurogenetic Testing Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next-Generation Sequencing (NGS)
• Southern Blotting
• Fluorescence In Situ Hybridization (FISH)
• Sanger Sequencing

7. Neurogenetic Testing Market Regional And Country Analysis

• 7.1. Global Neurogenetic Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurogenetic Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurogenetic Testing Market

• 8.1. Asia-Pacific Neurogenetic Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurogenetic Testing Market

• 9.1. China Neurogenetic Testing Market Overview
• 9.2. China Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurogenetic Testing Market

• 10.1. India Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurogenetic Testing Market

• 11.1. Japan Neurogenetic Testing Market Overview
• 11.2. Japan Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurogenetic Testing Market

• 12.1. Australia Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurogenetic Testing Market

• 13.1. Indonesia Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurogenetic Testing Market

• 14.1. South Korea Neurogenetic Testing Market Overview
• 14.2. South Korea Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurogenetic Testing Market

• 15.1. Western Europe Neurogenetic Testing Market Overview
• 15.2. Western Europe Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurogenetic Testing Market

• 16.1. UK Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurogenetic Testing Market

• 17.1. Germany Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurogenetic Testing Market

• 18.1. France Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurogenetic Testing Market

• 19.1. Italy Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurogenetic Testing Market

• 20.1. Spain Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurogenetic Testing Market

• 21.1. Eastern Europe Neurogenetic Testing Market Overview
• 21.2. Eastern Europe Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurogenetic Testing Market

• 22.1. Russia Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurogenetic Testing Market

• 23.1. North America Neurogenetic Testing Market Overview
• 23.2. North America Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurogenetic Testing Market

• 24.1. USA Neurogenetic Testing Market Overview
• 24.2. USA Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurogenetic Testing Market

• 25.1. Canada Neurogenetic Testing Market Overview
• 25.2. Canada Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurogenetic Testing Market

• 26.1. South America Neurogenetic Testing Market Overview
• 26.2. South America Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurogenetic Testing Market

• 27.1. Brazil Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurogenetic Testing Market

• 28.1. Middle East Neurogenetic Testing Market Overview
• 28.2. Middle East Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurogenetic Testing Market

• 29.1. Africa Neurogenetic Testing Market Overview
• 29.2. Africa Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurogenetic Testing Market Competitive Landscape And Company Profiles

• 30.1. Neurogenetic Testing Market Competitive Landscape
• 30.2. Neurogenetic Testing Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Diagnostics Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Laboratory Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

31. Neurogenetic Testing Market Other Major And Innovative Companies

• 31.1. Eurofins Scientific Inc.
• 31.2. Agilent Technologies Inc.
• 31.3. PerkinElmer Inc.
• 31.4. Illumina Inc.
• 31.5. Bio-Rad Laboratories Inc.
• 31.6. QIAGEN N.V.
• 31.7. Exact Sciences Corporation
• 31.8. Myriad Genetics Inc.
• 31.9. BioReference Laboratories Inc.
• 31.10. Connecticut Children's
• 31.11. Invitae Corp.
• 31.12. Ambry Genetics Corporation
• 31.13. Fulgent Genetics Inc.
• 31.14. Blueprint Genetics Inc.
• 31.15. GeneDx LLC

32. Global Neurogenetic Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurogenetic Testing Market

34. Recent Developments In The Neurogenetic Testing Market

35. Neurogenetic Testing Market High Potential Countries, Segments and Strategies

• 35.1 Neurogenetic Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurogenetic Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurogenetic Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer